ArticleEULAR rheumatology open2026
The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still's disease.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to formulate European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) regarding the development of criteria for the assessment of the disease activity in adult-onset Still's disease (AOSD). Methods: The Task Force consisted of 23 members from 7 different European countries. A systematic literature review and a 3-round Delphi exercise involving European Experts were conducted to support the formulation of overarching principles and PtCs. Results: Based on retrieved evidence and Experts' opinions, results of Delphi Rounds, and discussions, 3 overarching principles and 11 PtCs were developed. The Task Force agreed on the importance of an appropriate definition for the disease activity in AOSD to be valid, reliable, and easily transferable in a clinical setting. The development of specific criteria for the assessment of disease activity should include a precise definition of the clinical features that could better describe the patient condition. A clear definition of disease activity would help clinicians to adjust therapy and to identify refractory patients. A validated assessment of the disease activity is important to establish specifically designed and powered studies for comprehensive management of patients with AOSD. A uniform and reproducible definition of remission may facilitate the inclusion of a new therapeutic target into daily practice and clinical trials. Conclusions: The EULAR PtCs were produced regarding the development of criteria for the assessment of the disease activity in AOSD, to provide the basis for a clinical tool to be readily, reliably, and easily applied in clinical settings in order to improve patient management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.